Literature DB >> 731413

Pharmacokinetics of methotrexate in leukemia cells: effect of dose and mode of injection.

J M Weissbrod, R K Jain, F M Sirotnak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 731413     DOI： 10.1007/bf01062105

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  20 in total

1.  Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.

Authors:  F M Sirotnak; R C Donsback
Journal:  Cancer Res       Date:  1975-07       Impact factor: 12.701

2.  Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.

Authors:  F M Sirotnak; R C Donsbach; D M Dorick; D M Moccio
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

3.  Antifolate transport in L1210 leukemia cells. Kinetic evidence for the non-identity of carriers for influx and efflux.

Authors:  M Dembo; F M Sirotnak
Journal:  Biochim Biophys Acta       Date:  1976-10-19

4.  Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell.

Authors:  F M Sirotnak; R C Donsbach
Journal:  Cancer Res       Date:  1972-10       Impact factor: 12.701

5.  Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.

Authors:  F M Sirotnak; R C Donsbach
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

6.  Uptake of methotrexate, aminopterin, and methasquin and inhibition of dihydrofolate reductase and of DNA synthesis in mouse small intestine.

Authors:  F S Philips; F M Sirotnak; J E Sodergren; D J Hutchison
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

7.  The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic acid reductase and of DNA synthesis.

Authors:  S Margolis; F S Philips; S S Sternberg
Journal:  Cancer Res       Date:  1971-12       Impact factor: 12.701

8.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

9.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

10.  The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma.

Authors:  R J Lutz; R L Dedrick; J A Straw; M M Hart; P Klubes; D S Zaharko
Journal:  J Pharmacokinet Biopharm       Date:  1975-04
View more
  4 in total

1.  Pharmacokinetics of methotrexate in solid tumors.

Authors:  R K Jain; J Wei; P M Gullino
Journal:  J Pharmacokinet Biopharm       Date:  1979-04

Review 2.  The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

Authors:  Qingyu Zhou; James M Gallo
Journal:  AAPS J       Date:  2011-01-19       Impact factor: 4.009

3.  Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats.

Authors:  J M Gallo; P Varkonyi; E E Hassan; D R Groothius
Journal:  J Pharmacokinet Biopharm       Date:  1993-10

Review 4.  Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.

Authors:  Triantafyllos Stylianopoulos; Lance L Munn; Rakesh K Jain
Journal:  Trends Cancer       Date:  2018-03-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.